Since the breakthrough of coronavirus disease (COVID-19) more than 3 million people died worldwide1 and different vaccines were developed, tested in phase III clinical trials and used in the general population. Few reports of moderate-to-severe thrombocytopenia and thromboses (especially cerebral-venous and splanchnicvein thromboses) developing approximately 4-14 days after vaccination were reported. These events were related to the adenovirus vector–based DNA vaccines ChAdOx1 nCoV-19 (Oxford–AstraZeneca)2,3,4 or Ad26.COV2.S (Johnson&Johnson/Janssen).5 Recently, this new rare autoimmune syndrome that mimics heparin-induced thrombocytopenia (HIT)3 was defined as vaccine-induced immune thrombotic thrombocytopenia (VITT).4 Even though details on the pathophysiology are still scanty, diagnostic and therapeutic recommendations were proposed by international scientific organizations. 6-8 No definite data on risk factors are reported and it is unknown whether or not the therapeutic options currently adopted for HIT are also valid for VITT.
With this background, we describe an Italian case of severe VITT-related cerebral venous thrombosis (CVT) and bi-hemispheric hemorrhage, which was successfully treated with argatroban, intravenous immunoglobulin (IVIG) and corticosteroids. The case report is described according to CARE (CAse REport)-statement and checklist. 9
A previously healthy 26-year-old female presented to the emergency department 14 days after the first injection of ChAdOx1 nCoV-19 vaccine with a headache nonresponsive to anti-inflammatory drugs. On admission, she had right-sided weakness and visual disturbances. She has been on combined (estrogen-progestogen) contraceptives for more than 10 years but her past medical history was otherwise unremarkable and there was no prior exposure to heparin.
While general examination and vital signs were normal, neurological examination found a severe right-sided weakness but no visual field defects. Computerised tomography (CT) scan at admission showed a hyperdense rectus sinus and vein of Galen (Figure 1A). Magnetic resonance imaging (MRI) venography showed multifocal venous thrombosis with bilateral occlusion of parietal cortical veins, straight sinus, vein of Galen, internal cerebral veins and inferior sagittal sinus. Transverse sinuses were also partially involved but still patent (Figure 1B). At the right parietal and left frontoparietal lobes an extensive venous infarction with hemorrhagic transformation was present (Figure 1C). D-dimer was dramatically raised to 12,204 mg/L (reference value <500 mg/L) and the platelet count was 134x109/L. Given her recent exposure to ChAdOx1 nCoV-19 and clinical presentation, she was first treated with fondaparinux (5 mg subcutaneously) and admitted her to the intensive care unit. Her clinical condition rapidly deteriorated with decreased consciousness, right-sided hemiplegia and complete Balint syndrome.
In order to perform an extensive hemostasis laboratory work-up before and after therapies, blood was collected at different time points (T0=April 13; T1=April 15, and T2=April 20, 2021) into vacuum-tubes containing 1/10 volumes of trisodium-citrate 0.109 M, K-EDTA or plain tubes. Activated partial thromboplastin time (aPTT), prothrombin time (PT), D-dimer, fibrinogen and factor (F)VIII were obtained. Platelet-factor 4 (PF4)–heparin IgG antibodies (aPF4) were evaluated by a commerciallyavailable enzyme-linked immunosorbant assay (ELISA) (Immucor, Waukesha, WI, USA). Platelet-activating antibodies were evaluated by a platelet-activation test (PAT).2,10 Platelet function was also evaluated by using the Total Thrombus-Formation Analysis device (T-TAS®, Zacros, Fujimori-Kogyo, Tokyo, Japan),11-12 a flow-chamber device that assesses platelet-mediated thrombus formation in capillary channels by means of the following parameters: area under the flow-pressure curve (AUC), occlusion start-time (OST) and occlusion time (OT). Thrombin generation (TG) was measured in plateletpoor plasma (PPP).13 Controls were plasma samples from subjects negative for aPF4 and normal TG.
PT, aPTT and fibrinogen were within the normal range; FV-Leiden and G20210A-prothrombin mutations were absent; antithrombin and protein C/S were normal; lupus anticoagulant and antiphospholipid antibodies were negative. Patient serum (T1) was positive to aPF4-heparin ELISA (OD=1.918, reference value <0.4) and was inhibited (OD<0.5) by 100 U/mL heparin. Patient serum (T1) showed strong platelet activation on PPP from two controls in the presence and absence of low-dose heparin, whereas control serum showed no platelet activation. Five days afterwards (T2), the patient serum showed significant reduction of aPF4 reactivity (OD=0.6) and no longer did activate platelets (Figure 2A to C). At T0, platelet thrombus formation was impaired, AUC was smaller and OT longer than the reference range. In contrast, at T1 and T2 thrombus stability improved and TTAS parameters as well as platelet count also improved (Figure 2D to F). Results at the time of hospital admission (T1) showed a marked state of hypercoagulability when compared to control, as indicated by short lag-time (8.5 minutes [min] vs. 21.3 min), increased thrombin-peak (289 nM vs. 115 nM), short time-to-peak (11.8 min vs. 26.2min), increased ETP (2,158 nM/min vs. 1,684 nM/min) and ETP-TM ratio (0.99 vs. 0.79) (Figure 3). FVIII, one of the most potent procoagulants, was higher (200 U/dL) than the upper limit of the reference range (<150 U/dL). In contrast PC, the physiological inhibitor to activated FVIII was normal (88 U/dL). The imbalance between FVIII and PC corresponded to an increased FVIII/PC ratio (2.3), considerably greater than the expected unity and consistently with the hypercoagulability shown by TG. There are potential limitations of the TG assessment. First, measurements (owing to assay complexity and limited blood volumes) were performed only in PPP. Therefore, the potential role of procoagulant platelets in supporting TG could not be assessed. Second, TG could not be assessed on samples obtained during the time course of the disease because soon after the onset of the symptoms and the preliminary diagnosis the patient was treated with anticoagulants, so that TG results would have been unreliable.
Considering the clinical conditions and laboratory results, IVIG (1 g/kg o.d. for 2 days) and dexamethasone (40 mg/day, for 4 days) were started.6-8 Owing to the possible need for a sudden decompressive neurosurgical intervention, anticoagulation with fondaparinux was replaced by the short-acting drug argatroban (starting dosage 1 mg/kg/min with an aPTT-ratio [patient/normal] target of 1.5-2.0). Argatroban was subsequently increased to 3 mg/kg/min.
The patient’s neurological conditions improved in the next few days. She was awake and fully responsive to stimuli with a progressive recovery of right upper-limb strength, partial optic ataxia and regression of apraxia. On a follow-up CT scan, the rectus sinus and the vein of Galen showed normal density with oedema in the brain tissue on both hemispheres (Figure 1D). Follow-up MRI venography showed restored venous flow in the rectus sinus and the vein of Galen; right internal cerebral vein and bilateral frontoparietal cortical veins were still occluded (Figure 1E), and the large intraparenchimal venous infarction was unchanged (Figure 1F).
In the next few days, platelet count progressively increased to 339x109/L and D-dimer decreased to normal levels, in parallel with a significant reduction of aPF4 reactivity after 3 days (OD=0.9), and after 1 week (OD=0.6) patient serum was no longer able to activate platelets (Figure 2). Currently (nearly 2 months after the onset of symptoms), the patient has moderate disability: she has no neuropsychological deficits, can walk unassisted for short distances (sustained clonus and spasticity coexist in her right leg) and her right arm almost fully recovered. Fondaparinux was replaced with oral vitamin K antagonist.
In summary, we report a case of 26-year-old female who developed VITT following the first dose of ChAdOx1 nCoV-19. The patient had high-titer aPF4 and signs of platelet activation. Various treatment regimens have been suggested for this rare syndrome, being all based on HIT-derived approaches. Our treatment protocol, based upon IVIG, dexamethasone and argatroban was successful with almost complete clinical, laboratory and radiological response.
VITT should be considered in post-vaccination cases of thrombosis at unusual sites, even when apparent prothrombotic risk factors are identified (oral contraceptives in our case) and irrespective of the baseline platelet count. Indeed, this patient had mild thrombocytopenia on admission, but historical testing carried out before VITT recorded a platelet count of 275x109/L. Thus, the platelet count had decreased by approximately 50%, in agreement with HIT and VITT diagnostic criteria. Aware of the possible diagnosis of VITT, we initially avoided a potentially detrimental heparin treatment, and this decision is likely to have played a major role in determining the positive outcome.2,3 Another important decision was to promptly start immune modulating therapy which caused the reduction of aPF4 titer and D-dimer. The causative prothrombotic mechanism in the reported patient is likely to be due to the antibodies to PF4 that induced a strong platelet activation even in absence of heparin exposure. The fact that the patient started to improve soon after the antibody titer decreased strongly supports this mechanism. One of the potential mechanisms that can explain the loss of serum activity in the functional assays (PAT) could be the IVIG blockade of FCƴ platelet receptors and/or the antibody suppression. Interestingly, platelets’ ability to promote thrombus formation in vitro was greatly reduced at admission, probably as a consequence of in vivo platelet activation and the formation of exhausted platelets as observed in other pathological conditions such as disseminated intravascular coagulation or sepsis. Laboratory tests correlated well with the clinical and radiological course. All in all, our experience supports the application of an early and multidisciplinary therapeutic approach in cases of VITT, with the possibility to avoid fatalities and obtain a resolution of the syndrome as in this case.
- Received May 26, 2021
- Accepted July 2, 2021
Disclosures: no conflicts of interest to disclose
Contributions: SB managed the clinical case, collected clinical data and wrote the clinical part of the manuscript; AA, GS, CG and GPC managed the clinical case, collected clinical data and critically reviewed the manuscript; AL performed the laboratory assays, interpreted the results and contributed to writing the manuscript; SLM, LP and MC performed the laboratory assays; AT organized the hemostatic assays, interpreted the results and contributed to writing the manuscript; FP designed the study and wrote the manuscript. All authors read and approved the final manuscript.
this work was partially supported by the Italian Ministry of Health-Bando Ricerca Corrente 2020.
The authors thank Luigi Flaminio Ghilardini (Università degli Studi di Milano, Milan) for his help with figures.
- Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. JAMA. 2020; 324(08):782-793. https://doi.org/10.1001/jama.2020.12839Google Scholar
- Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S.. Thrombotic thrombocytopenia after ChAdOx1 nCov- 19 vaccination. N Engl J Med. 2021; 384(22):2092-2101. https://doi.org/10.1056/NEJMoa2104840Google Scholar
- Schultz NH, Sørvoll IH, Michelsen AE. Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination. N Engl J Med. 2021; 84(22):2124-2130. https://doi.org/10.1056/NEJMoa2104882Google Scholar
- Scully M, Singh D, Lown R. Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination. N Engl J Med. 2021; 384(23):2202-2211. https://doi.org/10.1056/NEJMoa2105385Google Scholar
- Muir KL, Kallam A, Koepsell SA, Gundabolu K.. Thrombotic thrombocytopenia after Ad26.COV2.S vaccination. N Engl J Med. 2021; 384(20):1964-1965. https://doi.org/10.1056/NEJMc2105869Google Scholar
- Oldenburg J, Klamroth R, Langer F. Diagnosis and management of vaccine-related thrombosis following AstraZeneca COVID- 19 vaccination: guidance statement from the GTH. Hamostaseologie. 2021; 41(3):184-189. https://doi.org/10.1055/a-1469-7481Google Scholar
- Nazy I, Sachs UJ, Arnold DM. Recommendations for the clinical and laboratory diagnosis of vaccine-induced immune thrombotic thrombocytopenia (VITT) for SARS-CoV-2 infections: communication from the ISTH SSC Subcommittee on Platelet Immunology. J Thromb Haemost. 2021; 19(6):1585-1588. https://doi.org/10.1111/jth.15341Google Scholar
- Gresele P, Marietta M, Ageno W. Management of cerebral and splanchnic vein thrombosis associated with thrombocytopenia in subjects previously vaccinated with Vaxzevria (AstraZeneca): a position statement from the Italian Society for the Study of Haemostasis and Thrombosis (SISET). Blood Transfus. 2021; 19(4):281-3. Google Scholar
- Riley DS, Barber MS, Kienle GS. CARE guidelines for case reports: explanation and elaboration document. J Clin Epidemiol. 2017; 89:218-235. https://doi.org/10.1016/j.jclinepi.2017.04.026Google Scholar
- Brodard J, Alberio L, Angelillo-Scherrer A, Nagler M.. Accuracy of heparin-induced platelet aggregation test for the diagnosis of heparin-induced thrombocytopenia. Thromb Res. 2020; 185:27-30. https://doi.org/10.1016/j.thromres.2019.11.004Google Scholar
- Hosokawa K, Ohnishi T, Kondo T. A novel automated microchip flow-chamber system to quantitatively evaluate thrombus formation and antithrombotic agents under blood flow conditions. J Thromb Haemost. 2011; 9(10):2029-2037. https://doi.org/10.1111/j.1538-7836.2011.04464.xGoogle Scholar
- Ghirardello S, Lecchi A, Artoni A. Assessment of platelet thrombus formation under flow conditions in adult patients with COVID-19: an observational study. Thromb Haemost. 2021; 121(8):1087-1096. https://doi.org/10.1055/s-0041-1722919Google Scholar
- Tripodi A. Detection of procoagulant imbalance. Modified endogenous thrombin potential with results expressed as ratio of values with-to-without thrombomodulin. Thromb Haemost. 2017; 117(5):830-36. https://doi.org/10.1160/TH16-10-0806Google Scholar
- Cattaneo M, Cerletti C, Harrison P. Recommendations for the standardization of light transmission aggregometry: A consensus of the working party from the platelet physiology subcommittee of ssc/isth. J Thromb Haemost. 2013; 11(6):1183-1189. https://doi.org/10.1111/jth.12231Google Scholar
Figures & Tables
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.